Drug Shortage Report for TEVA-CANDESARTAN/HCTZ
Report ID | 86963 |
Drug Identification Number | 02395541 |
Brand name | TEVA-CANDESARTAN/HCTZ |
Common or Proper name | CANDESARTAN/HCTZ |
Company Name | TEVA CANADA LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | HYDROCHLOROTHIAZIDE CANDESARTAN CILEXETIL |
Strength(s) | 12.5MG 16MG |
Dosage form(s) | TABLET |
Route of administration | ORAL |
Packaging size | 30 |
ATC code | C09DA |
ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2019-06-18 |
Estimated end date | 2020-04-30 |
Actual end date | 2020-04-22 |
Shortage status | Resolved |
Updated date | 2020-04-23 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2019-06-18 | English | Compare |